Cytokinetics (CYTK)

Must be logged in to add this company to your watchlist.

Click here to login.

CYTK - NASDAQ - 3/12/2010 8:00 PM

3.37
Change 0.01
% Change 0.30%
Market Cap Revenue Growth Profit Margin Cash
$204.86M 76.04% -148.82% $121.58M
2921 / 4569 183 / 4568 4352 / 4566 1560 / 4096

For the September 2009 quarter, Cytokinetics spent 179.09% of gross profits on R&D and 70% on SGA expenses. Revenues rose 76.04% year-over-year to $5.51M. The company is trading at 8.22 times earnings(PE) and 2.45 times revenue(PSR). At the end of September 2009, Cytokinetics had $121.58M in cash on hand and $1.33M in long-term debt. On 10/28/2009, Cytokinetics reported net loss of $8.20M, with diluted earnings per share of $-0.14.

Valuation

Add More Charts

Price

Current stock price.

PE Ratio: 8.22

Price paid for a share relative to the annual income earned.

Price to Sales Ratio: 2.45

Market cap divided by revenue.

Growth & Profitability

Add More Charts

Revenue Growth: 76.04%

Revenue growth year-over-year.

Earnings per Share: $-0.14

Portion of profit allocated to each outstanding share of common stock.

Profit Margin: -148.82%

Margin made on every dollar of revenue.

Fundamentals

Add More Charts

Income Statement

Summary of revenues, expenses & profits.

Balance Sheet

Company's assets, liabilities & shareholders' equity at a specific point in time.

Cash Flow

Cash inflows arise from one of three activities - operations, financing, or investing.